Advertisement
MEDP vs TMO
Which Stock Would AI Choose? Medpace Holdings, Inc. (MEDP) vs. Thermo Fisher Scientific Inc. (TMO) Stock Comparison
Key Takeaways
- Medpace Holdings, Inc. (MEDP) operates as a specialized clinical research organization, while Thermo Fisher Scientific Inc. (TMO) provides a broader portfolio of life sciences tools, diagnostics, and services.
- Both stocks have shown resilience in the healthcare sector amid ongoing volatility, with MEDP demonstrating stronger one-year returns compared to TMO's more moderate gains.
- Recent market activity reflects anticipation of upcoming quarterly earnings, with MEDP scheduled to report on July 22, 2026, and TMO on July 23, 2026.
- Valuation metrics and growth drivers differ, with MEDP tied closely to clinical trial demand and TMO benefiting from diversified exposure across research and biopharma end markets.
- Sector sentiment remains constructive for life sciences, though relative performance highlights trade-offs in stability versus specialized momentum.
- AI-driven analysis of trends and positioning suggests nuanced preferences based on consistency and catalysts rather than outright superiority.
Introduction
Medpace Holdings, Inc. (MEDP) and Thermo Fisher Scientific Inc. (TMO) represent distinct segments within the healthcare and life sciences industries, making them relevant for comparison among investors seeking exposure to clinical development and scientific instrumentation. Traders and portfolio managers focused on relative performance, sector rotation, and growth-oriented equities may find this analysis useful for assessing positioning in a market environment influenced by earnings cycles and macroeconomic factors. The comparison emphasizes verifiable fundamentals, recent price behavior, and observable market dynamics without forward-looking projections.
MEDP Overview and Recent Performance
Medpace Holdings, Inc. (MEDP) is a global contract research organization that delivers clinical development services to pharmaceutical, biotechnology, and medical device companies. Its model centers on managing clinical trials from Phase I through post-approval studies. In recent weeks, the stock has traded near levels around $538, reflecting a one-year total return exceeding 68% amid sustained demand for outsourced clinical services. Recent market activity shows measured price behavior ahead of the company's second-quarter 2026 earnings release scheduled for July 22, with broader sentiment supported by prior quarterly results that demonstrated revenue expansion. Factors influencing performance include steady backlog visibility and sector tailwinds in drug development pipelines.
TMO Overview and Recent Performance
Thermo Fisher Scientific Inc. (TMO) is a leading provider of scientific instruments, reagents, consumables, and services that support research, diagnostics, and biopharmaceutical manufacturing. The company serves academic, government, and industrial customers across multiple end markets. In recent weeks, shares have fluctuated around $532 following a session close of $532.48 on July 17, with one-year returns near 26% and year-to-date performance in the mid-single digits. Recent market activity includes positioning ahead of the second-quarter 2026 earnings report expected on July 23, alongside continued execution on prior initiatives such as the Clario acquisition completed earlier in the year. Sentiment has been shaped by stable demand in life sciences tools and diagnostics amid evolving healthcare spending patterns.
Trending AI Robots
Tickeron maintains a curated selection of AI trading bots through its Trending AI Robots page. The platform offers hundreds of AI Trading Bots that trade thousands of different tickers across varied market conditions, yet only the highest-performing and most suitable strategies for prevailing environments are featured in this section. Available bots exhibit a wide range of trading styles, strategies, timeframes, performance statistics, and ticker coverage, with many demonstrating success rates between 60% and 80% alongside varied drawdown profiles in historical testing. Users can explore these options to identify alignments with specific risk tolerances and market views. Review the full selection on the Trending AI Robots page for detailed metrics.
Head-to-Head Comparison
Medpace Holdings, Inc. (MEDP) and Thermo Fisher Scientific Inc. (TMO) differ fundamentally in business models: MEDP focuses exclusively on clinical trial management as a contract research organization, creating direct sensitivity to pharmaceutical research and development budgets, whereas TMO operates across a diversified life sciences ecosystem encompassing instruments, reagents, and contract manufacturing. Growth drivers contrast accordingly, with MEDP benefiting from clinical outsourcing trends and TMO from broader instrumentation demand and acquisitions such as Clario. Recent momentum shows MEDP with more pronounced one-year gains relative to TMO's steadier but lower trajectory. Risk factors include MEDP's higher concentration in trial execution and potential project variability, while TMO faces exposure to capital equipment cycles and integration of recent deals. Sector exposure places both in healthcare, though MEDP is narrower within biopharma services and TMO spans research tools and diagnostics. Market sentiment reflects comparable anticipation of earnings releases, with relative positioning favoring specialization for MEDP versus scale for TMO.
Tickeron AI Verdict
Based on observable factors such as trend consistency in recent periods, earnings visibility, and relative sector positioning, Tickeron’s AI models currently indicate a probabilistic tilt toward Medpace Holdings, Inc. (MEDP) due to stronger recent momentum and specialized demand alignment, though Thermo Fisher Scientific Inc. (TMO) offers advantages in diversification and stability. This assessment remains conditional on evolving data and does not constitute definitive guidance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MEDP is a StrongBuy and TMO is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MEDP’s FA Score shows that 2 FA rating(s) are green whileTMO’s FA Score has 1 green FA rating(s).
- MEDP’s FA Score: 2 green, 3 red.
- TMO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MEDP’s TA Score shows that 5 TA indicator(s) are bullish while TMO’s TA Score has 6 bullish TA indicator(s).
- MEDP’s TA Score: 5 bullish, 3 bearish.
- TMO’s TA Score: 6 bullish, 4 bearish.
Price Growth
MEDP (@Medical Specialties) experienced а +11.84% price change this week, while TMO (@Medical Specialties) price change was +6.72% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -1.55%. For the same industry, the average monthly price growth was +2.80%, and the average quarterly price growth was +1.12%.
Reported Earning Dates
MEDP is expected to report earnings on Oct 26, 2026.
TMO is expected to report earnings on Oct 28, 2026.
Industries' Descriptions
@Medical Specialties (-1.55% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| MEDP | TMO | MEDP / TMO | |
| Capitalization | 16.8B | 211B | 8% |
| EBITDA | 591M | 11.7B | 5% |
| Gain YTD | 7.074 | -1.736 | -408% |
| P/E Ratio | 35.33 | 30.58 | 116% |
| Revenue | 2.68B | 45.2B | 6% |
| Total Cash | 653M | 1.12B | 58% |
| Total Debt | 122M | 43.2B | 0% |
MEDP | TMO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 86 | 33 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 80 Overvalued | 12 Undervalued | |
PROFIT vs RISK RATING 1..100 | 26 | 80 | |
SMR RATING 1..100 | 15 | 62 | |
PRICE GROWTH RATING 1..100 | 37 | 40 | |
P/E GROWTH RATING 1..100 | 41 | 37 | |
SEASONALITY SCORE 1..100 | 50 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TMO's Valuation (12) in the Medical Specialties industry is significantly better than the same rating for MEDP (80) in the Miscellaneous Commercial Services industry. This means that TMO’s stock grew significantly faster than MEDP’s over the last 12 months.
MEDP's Profit vs Risk Rating (26) in the Miscellaneous Commercial Services industry is somewhat better than the same rating for TMO (80) in the Medical Specialties industry. This means that MEDP’s stock grew somewhat faster than TMO’s over the last 12 months.
MEDP's SMR Rating (15) in the Miscellaneous Commercial Services industry is somewhat better than the same rating for TMO (62) in the Medical Specialties industry. This means that MEDP’s stock grew somewhat faster than TMO’s over the last 12 months.
MEDP's Price Growth Rating (37) in the Miscellaneous Commercial Services industry is in the same range as TMO (40) in the Medical Specialties industry. This means that MEDP’s stock grew similarly to TMO’s over the last 12 months.
TMO's P/E Growth Rating (37) in the Medical Specialties industry is in the same range as MEDP (41) in the Miscellaneous Commercial Services industry. This means that TMO’s stock grew similarly to MEDP’s over the last 12 months.
| MEDP | TMO | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 86% | 2 days ago 61% |
| Stochastic ODDS (%) | 2 days ago 80% | 2 days ago 60% |
| Momentum ODDS (%) | 2 days ago 75% | 2 days ago 59% |
| MACD ODDS (%) | 2 days ago 83% | 2 days ago 66% |
| TrendWeek ODDS (%) | 2 days ago 76% | 2 days ago 61% |
| TrendMonth ODDS (%) | 2 days ago 76% | 2 days ago 61% |
| Advances ODDS (%) | 16 days ago 76% | 3 days ago 61% |
| Declines ODDS (%) | 6 days ago 63% | 5 days ago 63% |
| BollingerBands ODDS (%) | 2 days ago 76% | 2 days ago 63% |
| Aroon ODDS (%) | 2 days ago 76% | 2 days ago 59% |
Advertisement
MEDP and
Correlation & Price change
A.I.dvisor indicates that over the last year, MEDP has been loosely correlated with CRL. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if MEDP jumps, then CRL could also see price increases.
| Ticker / NAME | Correlation To MEDP | 1D Price Change % | ||
|---|---|---|---|---|
| MEDP | 100% | -0.73% | ||
| CRL - MEDP | 53% Loosely correlated | -1.18% | ||
| TMO - MEDP | 47% Loosely correlated | -0.71% | ||
| BRKR - MEDP | 43% Loosely correlated | -2.74% | ||
| RVTY - MEDP | 39% Loosely correlated | -2.39% | ||
| ICLR - MEDP | 39% Loosely correlated | -2.68% | ||
More | ||||